Results 181 to 190 of about 8,510 (199)

Lorlatinib in TKI-naïve patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from India.

Journal of Clinical Oncology
e20679 Background: Lorlatinib is a novel brain penetrant 3rd generation anaplastic lymphoma kinase (ALK)- inhibitor, approved as frontline & subsequent line therapy in ALK-rearranged advanced non-small cell lung cancer (NSCLC).
Ullas Batra, Somnath Roy, N. Menon, N. Warrier, Akhil Kapoor, Sajjan Rajpurohit, S. Rajappa, R. Thirumalairaj, Suresh Hariram Advani, Nishtha Sehra, Ankita Jain   +10 more
semanticscholar   +1 more source

Lorlatinib

Reactions Weekly, 2018
  +4 more sources

Crizotinib/lorlatinib

Reactions Weekly, 2022
  +4 more sources

First-Line Alectinib, Brigatinib, and Lorlatinib for Advanced ALK-Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.

Value in Health
R. Mudumba, Jorge J. Nieva, W. Padula
semanticscholar   +1 more source

Based on the CROWN Findings, Lorlatinib Should Be the Preferred First-Line Treatment for Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology
Hui Jing Hoe, Benjamin J. Solomon
semanticscholar   +1 more source

Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report.

Journal of Thoracic Oncology
Atsushi Yanagisawa, T. Shiroyama, K. Miyake, Y. Takeda, Atsushi Kumanogoh   +4 more
semanticscholar   +1 more source

Discovery of an ALK degrader for lorlatinib-resistant compound mutations.

European journal of medicinal chemistry
Fei Gao, Zhenhua Wu, Anqi Lin, Xinyu Wu, Baoding Zhang, Liqing Liu, Yue Lu, Shangshang Geng, Zhen Huang, Yiyu Chen, Jianming Zhang, Li Li, Xianming Deng   +12 more
semanticscholar   +1 more source

Alectinib/lorlatinib

Reactions Weekly, 2022
openaire   +1 more source

[Lorlatinib primary hospital patient health management expert consensus (2025 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology]

semanticscholar   +1 more source

Alectinib/crizotinib/lorlatinib

Reactions weekly

semanticscholar   +1 more source